


## QTX125

<b>Cat. No.:</b>	HY-120448
<b>CAS No.:</b>	1279698-31-5
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>19</sub> N <sub>3</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	417.41
<b>Target:</b>	HDAC; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	HDAC6																
<b>In Vitro</b>	<p>QTX125 (25-500 nM; 24-48 hours) treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP<sup>[1]</sup>.</p> <p>In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin<sup>[1]</sup>.</p> <p>QTX125 has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL)<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MINO, REC-1, IRM-2 and HBL-2 cells</td> </tr> <tr> <td>Concentration:</td> <td>25 nM, 50 nM, 100 nM, 500 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours, 48 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited annexin V/propidium iodide double staining.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MINO, REC-1, IRM-2 and HBL-2 cells</td> </tr> <tr> <td>Concentration:</td> <td>25 nM, 50 nM, 100 nM, 500 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP.</td> </tr> </table>	Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells	Concentration:	25 nM, 50 nM, 100 nM, 500 nM	Incubation Time:	24 hours, 48 hours	Result:	Inhibited annexin V/propidium iodide double staining.	Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells	Concentration:	25 nM, 50 nM, 100 nM, 500 nM	Incubation Time:	24 hours	Result:	Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP.
Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells																
Concentration:	25 nM, 50 nM, 100 nM, 500 nM																
Incubation Time:	24 hours, 48 hours																
Result:	Inhibited annexin V/propidium iodide double staining.																
Cell Line:	MINO, REC-1, IRM-2 and HBL-2 cells																
Concentration:	25 nM, 50 nM, 100 nM, 500 nM																
Incubation Time:	24 hours																
Result:	Inhibited the cleavage of caspase-9, caspase-8, caspase-3, and PARP.																
<b>In Vivo</b>	<p>QTX125 (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																

Animal Model:	Nude mice bearing REC-1 or MINO cells <sup>[1]</sup>
Dosage:	60 mg/kg
Administration:	Intraperitoneal administration; daily dosing for 5 days; for 4 weeks
Result:	Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice.

## REFERENCES

[1]. Montserrat Pérez-Salvia, et al. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. *Haematologica*. 2018 Nov;103(11):e537-e540.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA